Eventide
VC Fund
Omaha, United States
Eventide is a VC fund in Omaha focused on Biotechnology and Health Care. Evantide Asset Management, LLC provides investments for individuals, financial advisors, and institutions.
- Total investments:
- 60
- Last investment:
- Lead investor:
- 25%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Eventide invests in
BiotechnologyHealth CareTherapeuticsMedicalPharmaceutical
Stages Eventide invests in
Series BPost-IPO EquitySeries CSeries DPrivate Equity
Countries Eventide invests in
United StatesUnited KingdomChinaCanadaFrance
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dolores Bamford
|
|||
Finny Kuruvilla
|
|||
Robin Cheriakalath John
|
|||
2 more contacts available
Investment Focus
Industry
- Biotechnology 39 (65%)
- Health Care 27 (45%)
- Therapeutics 17 (28%)
- Medical 14 (23%)
- Pharmaceutical 14 (23%)
Stage
- Series B 15 (25%)
- Post-IPO Equity 13 (22%)
- Series C 12 (20%)
- Series D 4 (7%)
- Private Equity 4 (7%)
Country
- United States 40 (67%)
- United Kingdom 2 (3%)
- China 1 (2%)
- Canada 1 (2%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dolores Bamford
Co-Chief Investment Officer
|
Co-Chief Investment Officer | Total investments: 0 | Find email | |
|
Finny Kuruvilla
Chief Investment Officer, Portfolio Manager
|
Chief Investment Officer, Portfolio Manager | Total investments: 3 | Find email | |
|
Robin Cheriakalath John
Co-founder and Chief Executive Officer
|
Co-founder and Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Leo Cancer Care
|
Leo Cancer Care develops radiation therapy technologies that support cancer treatment in an upright patient position. The company designs integrated imaging, patient positioning, and treatment systems that are compatible with fixed radiation beam platforms used in photon and particle therapy. Its technology focuses on supporting the radiotherapyworkflow from patient simulation through treatment while enabling multiple radiation therapy modalities. Leo Cancer Care also collaborates with healthcare providers, research institutions, and industry partners to evaluate and advance the clinical use of upright radiotherapy systems. In addition to developing treatment technologies, the company works on expanding access to radiotherapy through solutions that aim to improve workflow efficiency and compatibility with existing treatment infrastructure. | $65M / Series D / Jul 08, 2026 | |
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
Quince Therapeutics
|
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | |
Adlai Nortye
|
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M / Post-IPO Equity / Apr 16, 2026 | |
Ovid Therapeutics
|
Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M / Post-IPO Equity / Mar 17, 2026 | |
Relmada Therapeutics
|
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M / Post-IPO Equity / Mar 09, 2026 | |
Sutro Biopharma
|
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $110M / Post-IPO Equity / Feb 10, 2026 | |
|
Ovid Therapeutics
|
Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $81M / Post-IPO Equity / Oct 03, 2025 | |
Belite Bio
|
Belite Bio focused on first-in-class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic age-related macular degeneration, stargardt disease, and nonalcoholic steatohepatitis. They develop anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration,liver disease, and diabetes. Their technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease, and diabetes. | $125M / Post-IPO Equity / Sep 08, 2025 | |
BBOT
|
BridgeBio Oncology Therapeutics operates as a biopharmaceutical company. | $261M / Post-IPO Equity / Aug 11, 2025 | |
| See all 60 investments → | |||
Co-Investors
Surveyor Capital
16 deals together
RA Capital Management
14 deals together
Perceptive Advisors
11 deals together
Janus Henderson Investors
10 deals together
Soleus Capital
10 deals together
Cowen Healthcare Investments
9 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Eventide invest in?
Eventide invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 60 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eventide?
Public channels for Eventide include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eventide?
The team at Eventide includes Dolores Bamford (Co-Chief Investment Officer), Finny Kuruvilla (Chief Investment Officer, Portfolio Manager) and Robin Cheriakalath John (Co-founder and Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
